Medicus Pharma Ltd(MDCX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -48.55 | Insider Own | 22.91% | Shs Outstand | 1.9M | Perf Week | -12.77% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 51.37% | Insider Trans | - | Shs Float | 0.2M | Perf Month | -50% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -4.44 | Inst Own | 29.69% | Short Float | 34.48% | Perf Quarter | -90.73% |
| Income | -0.04B | P/S | - | EPS this Y | 77.32% | Inst Trans | - | Short Ratio | 0.56 | Perf Half Y | -89.75% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 53.77% | ROA | -364.14% | Short Interest | 0.06M | Perf YTD | -97.86% |
| Book/sh | -4.01 | P/C | 0.89 | EPS past 3/5Y | -129.98% - | ROE | -5705.59% | 52W High | -98.71% ($127.50) | Perf Year | -98.54% |
| Cash/sh | 1.84 | P/FCF | - | Sales past 3/5Y | - | ROIC | -1008.42% | 52W Low | -3.53% ($1.70) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.61% | Gross Margin | - | Volatility(W/M) | 15.87% 14.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.65 | EPS Q/Q | 79.62% | Profit Margin | - | RSI (14) | 18.31 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.65 | Sales Q/Q | - | SMA20 | -29.04% ($2.31) | Beta | -0.01 | Target Price | $121.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/9 | SMA50 | -70.03% ($5.47) | Rel Volume | 0.48 | Prev Close | $1.83 |
| Employees | 16 | LT Debt/Eq | - | EPS/Sales Surpr. | -97.06% - | SMA200 | -91.91% ($20.27) | Avg Volume(3M) | 0.11M | Price | $1.64 |
| IPO | 2024/1/26 | Option/Short | No/Yes | Trades | 358 | Volume | 53,588 | Change | -10.38% |
💉 Medicus Pharma() is a clinical-stage biotech developing a non-surgical treatment for basal cell carcinoma (BCC) using <strong>microneedle (tiny needle) patch-based drug delivery</strong> technology. Its lead candidate, <strong>SkinJect (D-MNA)</strong>, delivers the anti-cancer agent doxorubicin through a microneedle array directly into skin lesions, and positive response data have been observed in Phase 2 clinical trials.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 48% of its average volume.
MDCX has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +77.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
34.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% It ranks #21 of 21 in the industry
Based on market cap of $3M.
AMRN#17 Amarin Corp ADR $247M PER - 
NSRX#18 Nasus Pharma Ltd $34M PER - 
MIRA#19 Mira Pharmaceuticals Inc $26M PER - 
SCLX#20 Scilex Holding Company $11M PER - MDCX#21 Medicus Pharma Ltd $3M PER - 
FAQ
What kind of company is MDCX?
MDCX belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of MDCX?
The market cap of MDCX is approximately $3M, ranking 5,706 within its sector.
What is the 52-week high and low for MDCX?
MDCX has recorded a 52-week high of $127.50 and a low of $1.70.
